Loading…
RECOMBINANT HUMAN MACROPHAGE COLONY-STIMULATING FACTOR AUGMENTS PULMONARY HOST DEFENCES AGAINST ASPERGILLUS FUMIGATUS
The in vivo and ex vivo effects of macrophage colony-stimulating factor (M-CSF) were studied in a profoundly neutropenic rabbit model in order to determine its potential to augment pulmonary host defence againstAspergillus . M-CSF (100–600μg/kg/d) was administered prophylactically to neutropenic rab...
Saved in:
| Published in: | Cytokine (Philadelphia, Pa.) Pa.), 2001-07, Vol.15 (2), p.87-95 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 95 |
| container_issue | 2 |
| container_start_page | 87 |
| container_title | Cytokine (Philadelphia, Pa.) |
| container_volume | 15 |
| creator | Gonzalez, Corina E. Lyman, Caron A. Lee, Sondra Del Guercio, Carla Roilides, Emmanuel Bacher, John Gehrt, Andreas Feuerstein, Erwin Tsokos, Maria Walsh, Thomas J. |
| description | The in vivo and ex vivo effects of macrophage colony-stimulating factor (M-CSF) were studied in a profoundly neutropenic rabbit model in order to determine its potential to augment pulmonary host defence againstAspergillus . M-CSF (100–600μg/kg/d) was administered prophylactically to neutropenic rabbits with pulmonary aspergillosis starting three days pre-inoculation and then throughout neutropenia. Rabbits receiving M-CSF had significantly increased survival (P=0.01) and decreased pulmonary injury, as measured by decreased pulmonary infarction (P=0.004), when compared with untreated controls. Microscopic studies demonstrated greater numbers of activated pulmonary alveolar macrophages (PAMs) in lung tissue of rabbits receiving M-CSF, in comparison to controls (P |
| doi_str_mv | 10.1006/cyto.2001.0889 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71075013</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1043466601908890</els_id><sourcerecordid>71075013</sourcerecordid><originalsourceid>FETCH-LOGICAL-e256t-5a56f54b5d4e0b477b1c5d432a1a48a3c8878353223010bbb9800f1b0abee23d3</originalsourceid><addsrcrecordid>eNo1kbtvgzAQh62qVZOmXTtWnrqRnjEPZ3QpIUhgIh5DJguDI1HlVQiV8t8XlHS6350-nU73IfRKYE4AnI_qcj7OTQAyB8YWd2hKYOEYACa9H7NFDctxnAl66rpvAFhQ131EE0LsoWHWFPWp7yXxZyi4yPGqiLnAMffSZL3igY-9JErExsjyMC4inociwEvu5UmKeRHEvsgzvC6iOBE83eBVkuX4y1_6wvMzzAMeimHAs7WfBmEUFRleFnEY8LzIntHDttx1-uVWZ6hY-rm3MqIkCD0eGdq0nbNhl7aztS1l15YGZbmuItWQqVmS0mIlrRhzGbWpaVIgoJRaMIAtUVAqrU1a0xl6v-49tcefXndnuW-6Su925UEf-066BFwbCB3AtxvYq72u5alt9mV7kf-PGgB2BfRw7m-jW9lVjT5Uum5aXZ1lfWwkATk6kaMTOTqRoxP6B9BhdAY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71075013</pqid></control><display><type>article</type><title>RECOMBINANT HUMAN MACROPHAGE COLONY-STIMULATING FACTOR AUGMENTS PULMONARY HOST DEFENCES AGAINST ASPERGILLUS FUMIGATUS</title><source>ScienceDirect Journals</source><creator>Gonzalez, Corina E. ; Lyman, Caron A. ; Lee, Sondra ; Del Guercio, Carla ; Roilides, Emmanuel ; Bacher, John ; Gehrt, Andreas ; Feuerstein, Erwin ; Tsokos, Maria ; Walsh, Thomas J.</creator><creatorcontrib>Gonzalez, Corina E. ; Lyman, Caron A. ; Lee, Sondra ; Del Guercio, Carla ; Roilides, Emmanuel ; Bacher, John ; Gehrt, Andreas ; Feuerstein, Erwin ; Tsokos, Maria ; Walsh, Thomas J.</creatorcontrib><description>The in vivo and ex vivo effects of macrophage colony-stimulating factor (M-CSF) were studied in a profoundly neutropenic rabbit model in order to determine its potential to augment pulmonary host defence againstAspergillus . M-CSF (100–600μg/kg/d) was administered prophylactically to neutropenic rabbits with pulmonary aspergillosis starting three days pre-inoculation and then throughout neutropenia. Rabbits receiving M-CSF had significantly increased survival (P=0.01) and decreased pulmonary injury, as measured by decreased pulmonary infarction (P=0.004), when compared with untreated controls. Microscopic studies demonstrated greater numbers of activated pulmonary alveolar macrophages (PAMs) in lung tissue of rabbits receiving M-CSF, in comparison to controls (P<0.001). PAMs harvested from rabbits treated with M-CSF had a significantly greater percent phagocytosis ofAspergillus fumigatus conidia than did PAMs from controls (P=0.04). These data indicate that prophylactic administration of M-CSF augments pulmonary host defence against A. fumigatus and suggest a potential role for this cytokine as adjunctive therapy in the treatment of pulmonary aspergillosis in the setting of profound neutropenia.</description><identifier>ISSN: 1043-4666</identifier><identifier>EISSN: 1096-0023</identifier><identifier>DOI: 10.1006/cyto.2001.0889</identifier><identifier>PMID: 11500084</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Antifungal Agents - pharmacology ; Aspergillosis - drug therapy ; Aspergillosis - immunology ; Aspergillosis - pathology ; Aspergillus /Host defense/Macrophage-Colony-Stimulating factor/Pulmonary ; Aspergillus fumigatus - drug effects ; Female ; Humans ; Lung Diseases, Fungal - drug therapy ; Lung Diseases, Fungal - immunology ; Lung Diseases, Fungal - pathology ; Macrophage Colony-Stimulating Factor - pharmacology ; Macrophages - immunology ; Phagocytosis - drug effects ; Phagocytosis - immunology ; Pneumonia - drug therapy ; Pneumonia - microbiology ; Pneumonia - pathology ; Pulmonary Alveoli - pathology ; Pulmonary Embolism - drug therapy ; Pulmonary Embolism - pathology ; Rabbits ; Recombinant Proteins ; Survival Rate</subject><ispartof>Cytokine (Philadelphia, Pa.), 2001-07, Vol.15 (2), p.87-95</ispartof><rights>2001 Academic Press</rights><rights>Copyright 2001 Academic Press.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11500084$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gonzalez, Corina E.</creatorcontrib><creatorcontrib>Lyman, Caron A.</creatorcontrib><creatorcontrib>Lee, Sondra</creatorcontrib><creatorcontrib>Del Guercio, Carla</creatorcontrib><creatorcontrib>Roilides, Emmanuel</creatorcontrib><creatorcontrib>Bacher, John</creatorcontrib><creatorcontrib>Gehrt, Andreas</creatorcontrib><creatorcontrib>Feuerstein, Erwin</creatorcontrib><creatorcontrib>Tsokos, Maria</creatorcontrib><creatorcontrib>Walsh, Thomas J.</creatorcontrib><title>RECOMBINANT HUMAN MACROPHAGE COLONY-STIMULATING FACTOR AUGMENTS PULMONARY HOST DEFENCES AGAINST ASPERGILLUS FUMIGATUS</title><title>Cytokine (Philadelphia, Pa.)</title><addtitle>Cytokine</addtitle><description>The in vivo and ex vivo effects of macrophage colony-stimulating factor (M-CSF) were studied in a profoundly neutropenic rabbit model in order to determine its potential to augment pulmonary host defence againstAspergillus . M-CSF (100–600μg/kg/d) was administered prophylactically to neutropenic rabbits with pulmonary aspergillosis starting three days pre-inoculation and then throughout neutropenia. Rabbits receiving M-CSF had significantly increased survival (P=0.01) and decreased pulmonary injury, as measured by decreased pulmonary infarction (P=0.004), when compared with untreated controls. Microscopic studies demonstrated greater numbers of activated pulmonary alveolar macrophages (PAMs) in lung tissue of rabbits receiving M-CSF, in comparison to controls (P<0.001). PAMs harvested from rabbits treated with M-CSF had a significantly greater percent phagocytosis ofAspergillus fumigatus conidia than did PAMs from controls (P=0.04). These data indicate that prophylactic administration of M-CSF augments pulmonary host defence against A. fumigatus and suggest a potential role for this cytokine as adjunctive therapy in the treatment of pulmonary aspergillosis in the setting of profound neutropenia.</description><subject>Animals</subject><subject>Antifungal Agents - pharmacology</subject><subject>Aspergillosis - drug therapy</subject><subject>Aspergillosis - immunology</subject><subject>Aspergillosis - pathology</subject><subject>Aspergillus /Host defense/Macrophage-Colony-Stimulating factor/Pulmonary</subject><subject>Aspergillus fumigatus - drug effects</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Diseases, Fungal - drug therapy</subject><subject>Lung Diseases, Fungal - immunology</subject><subject>Lung Diseases, Fungal - pathology</subject><subject>Macrophage Colony-Stimulating Factor - pharmacology</subject><subject>Macrophages - immunology</subject><subject>Phagocytosis - drug effects</subject><subject>Phagocytosis - immunology</subject><subject>Pneumonia - drug therapy</subject><subject>Pneumonia - microbiology</subject><subject>Pneumonia - pathology</subject><subject>Pulmonary Alveoli - pathology</subject><subject>Pulmonary Embolism - drug therapy</subject><subject>Pulmonary Embolism - pathology</subject><subject>Rabbits</subject><subject>Recombinant Proteins</subject><subject>Survival Rate</subject><issn>1043-4666</issn><issn>1096-0023</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNo1kbtvgzAQh62qVZOmXTtWnrqRnjEPZ3QpIUhgIh5DJguDI1HlVQiV8t8XlHS6350-nU73IfRKYE4AnI_qcj7OTQAyB8YWd2hKYOEYACa9H7NFDctxnAl66rpvAFhQ131EE0LsoWHWFPWp7yXxZyi4yPGqiLnAMffSZL3igY-9JErExsjyMC4inociwEvu5UmKeRHEvsgzvC6iOBE83eBVkuX4y1_6wvMzzAMeimHAs7WfBmEUFRleFnEY8LzIntHDttx1-uVWZ6hY-rm3MqIkCD0eGdq0nbNhl7aztS1l15YGZbmuItWQqVmS0mIlrRhzGbWpaVIgoJRaMIAtUVAqrU1a0xl6v-49tcefXndnuW-6Su925UEf-066BFwbCB3AtxvYq72u5alt9mV7kf-PGgB2BfRw7m-jW9lVjT5Uum5aXZ1lfWwkATk6kaMTOTqRoxP6B9BhdAY</recordid><startdate>20010721</startdate><enddate>20010721</enddate><creator>Gonzalez, Corina E.</creator><creator>Lyman, Caron A.</creator><creator>Lee, Sondra</creator><creator>Del Guercio, Carla</creator><creator>Roilides, Emmanuel</creator><creator>Bacher, John</creator><creator>Gehrt, Andreas</creator><creator>Feuerstein, Erwin</creator><creator>Tsokos, Maria</creator><creator>Walsh, Thomas J.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20010721</creationdate><title>RECOMBINANT HUMAN MACROPHAGE COLONY-STIMULATING FACTOR AUGMENTS PULMONARY HOST DEFENCES AGAINST ASPERGILLUS FUMIGATUS</title><author>Gonzalez, Corina E. ; Lyman, Caron A. ; Lee, Sondra ; Del Guercio, Carla ; Roilides, Emmanuel ; Bacher, John ; Gehrt, Andreas ; Feuerstein, Erwin ; Tsokos, Maria ; Walsh, Thomas J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e256t-5a56f54b5d4e0b477b1c5d432a1a48a3c8878353223010bbb9800f1b0abee23d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Animals</topic><topic>Antifungal Agents - pharmacology</topic><topic>Aspergillosis - drug therapy</topic><topic>Aspergillosis - immunology</topic><topic>Aspergillosis - pathology</topic><topic>Aspergillus /Host defense/Macrophage-Colony-Stimulating factor/Pulmonary</topic><topic>Aspergillus fumigatus - drug effects</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Diseases, Fungal - drug therapy</topic><topic>Lung Diseases, Fungal - immunology</topic><topic>Lung Diseases, Fungal - pathology</topic><topic>Macrophage Colony-Stimulating Factor - pharmacology</topic><topic>Macrophages - immunology</topic><topic>Phagocytosis - drug effects</topic><topic>Phagocytosis - immunology</topic><topic>Pneumonia - drug therapy</topic><topic>Pneumonia - microbiology</topic><topic>Pneumonia - pathology</topic><topic>Pulmonary Alveoli - pathology</topic><topic>Pulmonary Embolism - drug therapy</topic><topic>Pulmonary Embolism - pathology</topic><topic>Rabbits</topic><topic>Recombinant Proteins</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gonzalez, Corina E.</creatorcontrib><creatorcontrib>Lyman, Caron A.</creatorcontrib><creatorcontrib>Lee, Sondra</creatorcontrib><creatorcontrib>Del Guercio, Carla</creatorcontrib><creatorcontrib>Roilides, Emmanuel</creatorcontrib><creatorcontrib>Bacher, John</creatorcontrib><creatorcontrib>Gehrt, Andreas</creatorcontrib><creatorcontrib>Feuerstein, Erwin</creatorcontrib><creatorcontrib>Tsokos, Maria</creatorcontrib><creatorcontrib>Walsh, Thomas J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Cytokine (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gonzalez, Corina E.</au><au>Lyman, Caron A.</au><au>Lee, Sondra</au><au>Del Guercio, Carla</au><au>Roilides, Emmanuel</au><au>Bacher, John</au><au>Gehrt, Andreas</au><au>Feuerstein, Erwin</au><au>Tsokos, Maria</au><au>Walsh, Thomas J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RECOMBINANT HUMAN MACROPHAGE COLONY-STIMULATING FACTOR AUGMENTS PULMONARY HOST DEFENCES AGAINST ASPERGILLUS FUMIGATUS</atitle><jtitle>Cytokine (Philadelphia, Pa.)</jtitle><addtitle>Cytokine</addtitle><date>2001-07-21</date><risdate>2001</risdate><volume>15</volume><issue>2</issue><spage>87</spage><epage>95</epage><pages>87-95</pages><issn>1043-4666</issn><eissn>1096-0023</eissn><abstract>The in vivo and ex vivo effects of macrophage colony-stimulating factor (M-CSF) were studied in a profoundly neutropenic rabbit model in order to determine its potential to augment pulmonary host defence againstAspergillus . M-CSF (100–600μg/kg/d) was administered prophylactically to neutropenic rabbits with pulmonary aspergillosis starting three days pre-inoculation and then throughout neutropenia. Rabbits receiving M-CSF had significantly increased survival (P=0.01) and decreased pulmonary injury, as measured by decreased pulmonary infarction (P=0.004), when compared with untreated controls. Microscopic studies demonstrated greater numbers of activated pulmonary alveolar macrophages (PAMs) in lung tissue of rabbits receiving M-CSF, in comparison to controls (P<0.001). PAMs harvested from rabbits treated with M-CSF had a significantly greater percent phagocytosis ofAspergillus fumigatus conidia than did PAMs from controls (P=0.04). These data indicate that prophylactic administration of M-CSF augments pulmonary host defence against A. fumigatus and suggest a potential role for this cytokine as adjunctive therapy in the treatment of pulmonary aspergillosis in the setting of profound neutropenia.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>11500084</pmid><doi>10.1006/cyto.2001.0889</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-4666 |
| ispartof | Cytokine (Philadelphia, Pa.), 2001-07, Vol.15 (2), p.87-95 |
| issn | 1043-4666 1096-0023 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71075013 |
| source | ScienceDirect Journals |
| subjects | Animals Antifungal Agents - pharmacology Aspergillosis - drug therapy Aspergillosis - immunology Aspergillosis - pathology Aspergillus /Host defense/Macrophage-Colony-Stimulating factor/Pulmonary Aspergillus fumigatus - drug effects Female Humans Lung Diseases, Fungal - drug therapy Lung Diseases, Fungal - immunology Lung Diseases, Fungal - pathology Macrophage Colony-Stimulating Factor - pharmacology Macrophages - immunology Phagocytosis - drug effects Phagocytosis - immunology Pneumonia - drug therapy Pneumonia - microbiology Pneumonia - pathology Pulmonary Alveoli - pathology Pulmonary Embolism - drug therapy Pulmonary Embolism - pathology Rabbits Recombinant Proteins Survival Rate |
| title | RECOMBINANT HUMAN MACROPHAGE COLONY-STIMULATING FACTOR AUGMENTS PULMONARY HOST DEFENCES AGAINST ASPERGILLUS FUMIGATUS |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T10%3A40%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RECOMBINANT%20HUMAN%20MACROPHAGE%20COLONY-STIMULATING%20FACTOR%20AUGMENTS%20PULMONARY%20HOST%20DEFENCES%20AGAINST%20ASPERGILLUS%20FUMIGATUS&rft.jtitle=Cytokine%20(Philadelphia,%20Pa.)&rft.au=Gonzalez,%20Corina%20E.&rft.date=2001-07-21&rft.volume=15&rft.issue=2&rft.spage=87&rft.epage=95&rft.pages=87-95&rft.issn=1043-4666&rft.eissn=1096-0023&rft_id=info:doi/10.1006/cyto.2001.0889&rft_dat=%3Cproquest_pubme%3E71075013%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-e256t-5a56f54b5d4e0b477b1c5d432a1a48a3c8878353223010bbb9800f1b0abee23d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71075013&rft_id=info:pmid/11500084&rfr_iscdi=true |